A Phase 3 interventional study of IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 23 sites in 5 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2023-09-07.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 49th largest by enrollment, is one of 10 that started in 2016, is one of 45 in phase 3, and was the 38th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 1 Month to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 10 started in 2016.
This study's enrollment of 57 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 72nd largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 62 in phase 3, and was the 49th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in participants with cystic fibrosis (CF) who are \<24 months of age at treatment initiation and have an ivacaftor-responsive CF transmembrane conductance regulator (CFTR) gene mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion Criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants weighing 5 to less than (\<) 7 kilogram (kg) received 25 milligram (mg) IVA, 7 to \<14 kg received 50 mg IVA, and those weighing 14 to \<25 kg received 75 mg IVA administered every 12 hours (q12h) on Days 1 through 3 and 1 morning dose on Day 4.
Drug: IVA
Participants 4 to \<6 months of age and weighing greater than or equal to (≥) 5 kg received 25 mg IVA q12h. At 6 months of age and older, participants weighing 5 to \<7 kg received 25 mg IVA, 7 to \<14 kg received 50 mg IVA, and those weighing 14 to \<25 kg received 75 mg IVA q12h for 24 weeks on Part B. For Part A/B, participants 1 to \<4 months weighing 3 kg to \<5 kg received an initial low dose of 5.7 mg q12h IVA and those weighing ≥5 kg received 11.4 mg q12h IVA for the first 15 days of IVA treatment. Doses were maintained or adjusted upward at Day 15 and based on weight and/or age once they reached 4 months of age.
Drug: IVA
Granules in sachet for oral administration.
Also known as: VX-770, ivacaftor
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)
Time frame: Day 1 through Day 70
Part A: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
Time frame: Pre-dose, 2-4 hours, 6-8 hours, 24-60 hours post-dose
Part B +A/B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)
Time frame: Day 1 through Week 38
Part A/B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
Time frame: Day 4 (pre-dose, 2-4 hours, 6-8 hours post-dose); Day 15 (pre-dose); Week 4 (pre-dose); Week 8 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 12 (pre-dose); Week 18 (pre-dose) and Week 24 (pre-dose)
Part B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
Time frame: Week 2 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 8 (pre-dose,1 hour, 4-hour post-dose); Week 24 (pre-dose, 2-4 hours post dose)
Part B + A/B: Absolute Change From Baseline in Sweat Chloride
Sweat samples were collected using an approved collection device.
Time frame: From Baseline at Week 24
This study was conducted in participants with cystic fibrosis (CF) who were less than (\<) 24 months of age at Day 1 and have an ivacaftor-responsive CF transmembrane conductance regulator (CFTR) mutation.
| Milestone | Part A: 3 to < 24 Months | Part B + A/B: 1 to < 24 Months |
|---|---|---|
| Started | 19 | 0 |
| Completed | 19 | 0 |
| Not completed | 0 | 0 |
| Milestone | Part A: 3 to < 24 Months | Part B + A/B: 1 to < 24 Months |
|---|---|---|
| Started | 0 | 43 |
| Completed | 0 | 40 |
| Not completed | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal of consent (not due to adverse event) | 0 | 1 |
| Participants | Part A: 3 to < 24 Months |
|---|---|
| Participants with TEAEs | 10 |
| Participants with Serious TEAEs | 1 |
| nanogram per milliliter (ng/ml) | Part A: 3 to < 24 Months |
|---|---|
| Pre dose: IVA | 654 ± 531 |
| Pre dose: M1-IVA | 1880 ± 1160 |
| Pre dose: M6-IVA | 2680 ± 1990 |
| 2-4 hrs post dose: IVA | 956 ± 497 |
| 2-4 hrs post dose: M1-IVA | 1990 ± 1160 |
| 2-4 hrs post dose: M6-IVA | 2460 ± 2110 |
| 6-8 hrs post dose: IVA | 1040 ± 623 |
| 6-8 hrs post dose: M1-IVA | 2440 ± 1260 |
| 6-8 hrs post dose: M6-IVA | 2880 ± 2180 |
| 24-60 hrs post dose: IVA | 129 ± 68.8 |
| 24-60 hrs post dose: M1-IVA | 508 ± 228 |
| 24-60 hrs post dose: M6-IVA | 1100 ± 982 |
| Participants | Part B + A/B: 1 to <24 Months |
|---|---|
| Participants with TEAEs | 38 |
| Participants with Serious (TEAEs) | 6 |
| ng/ml | Part A/B: 1 to <4 Months |
|---|---|
| Day 4 (pre dose): IVA | 348 ± 151 |
| Day 4 (pre dose): M1-IVA | 867 ± 412 |
| Day 4 (pre dose): M6-IVA | 1570 ± 570 |
| Day 4 (2-4 hrs post dose): IVA | 381 ± 135 |
| Day 4 (2-4 hrs post dose): M1-IVA | 851 ± 333 |
| Day 4 (2-4 hrs post dose): M6-IVA | 1370 ± 450 |
| Day 4 (6-8 hrs post dose): IVA | 501 ± 196 |
| Day 4 (6-8 hrs post dose): M1-IVA | 1190 ± 420 |
| Day 4 (6-8 hrs post dose): M6-IVA | 1670 ± 551 |
| Day 15 (pre dose): IVA | 191 ± 134 |
| Day 15 (pre dose): M1-IVA | 614 ± 378 |
| Day 15 (pre dose): M6-IVA | 1510 ± 1110 |
| Week 4 (pre dose): IVA | 316 ± 130 |
| Week 4 (pre dose): M1-IVA | 1170 ± 577 |
| Week 4 (pre dose): M6-IVA | 3370 ± 2330 |
| Week 8 (pre dose): IVA | 449 ± 352 |
| Week 8 (pre dose): M1-IVA | 1030 ± 476 |
| Week 8 (pre dose): M6-IVA | 2380 ± 1500 |
| Week 8 (2-4 hrs post dose): IVA | 523 ± 262 |
| Week 8 (2-4 hrs post dose): M1-IVA | 1360 ± 982 |
| Week 8 (2-4 hrs post dose): M6-IVA | 2100 ± 1540 |
| Week 8 (6-8 hrs post dose): IVA | 438 ± 79.8 |
| Week 8 (6-8 hrs post dose): M1-IVA | 1420 ± 606 |
| Week 8 (6-8 hrs post dose): M6-IVA | 2320 ± 1330 |
| Week 12 (pre dose): IVA | 213 ± 173 |
| Week 12 (pre dose): M1-IVA | 906 ± 660 |
| Week 12 (pre dose): M6-IVA | 2500 ± 1760 |
| Week 18 (pre dose): IVA | 226 ± 153 |
| Week 18 (pre dose): M1-IVA | 815 ± 470 |
| Week 18 (pre dose): M6-IVA | 2060 ± 1190 |
| Week 24 (pre dose): IVA | 276 ± 137 |
| Week 24 (pre dose): M1-IVA | 1120 ± 496 |
| Week 24 (pre dose): M6-IVA | 2380 ± 799 |
| ng/ml | Part B: 4 to <24 Months |
|---|---|
| Week 2 (pre dose): IVA | 457 ± 441 |
| Week 2 (pre dose): M1-IVA | 1340 ± 934 |
| Week 2 (pre dose): M6-IVA | 1980 ± 1790 |
| Week 2 (2-4 hrs post dose): IVA | 812 ± 726 |
| Week 2 (2-4 hrs post dose): M1-IVA | 1560 ± 1190 |
| Week 2 (2-4 hrs post dose): M6-IVA | 1770 ± 1970 |
| Week 2 (6-8 hrs post dose): IVA | 969 ± 705 |
| Week 2 (6-8 hrs post dose): M1-IVA | 2210 ± 1360 |
| Week 2 (6-8 hrs post dose): M6-IVA | 2140 ± 1880 |
| Week 8 (pre dose): IVA | 404 ± 376 |
| Week 8 (pre dose): M1-IVA | 1220 ± 782 |
| Week 8 (pre dose): M6-IVA | 1720 ± 1110 |
| Week 8 (1 hrs post dose): IVA | 466 ± 384 |
| Week 8 (1 hrs post dose): M1-IVA | 1100 ± 670 |
| Week 8 (1 hrs post dose): M6-IVA | 1500 ± 881 |
| Week 8 (4 hrs post dose): IVA | 996 ± 520 |
| Week 8 (4 hrs post dose): M1-IVA | 2130 ± 950 |
| Week 8 (4 hrs post dose): M6-IVA | 1750 ± 1010 |
| Week 24 (pre dose): IVA | 301 ± 204 |
| Week 24 (pre dose): M1-IVA | 1050 ± 492 |
| Week 24 (pre dose): M6-IVA | 1600 ± 783 |
| Week 24 (2-4 hrs post dose): IVA | 794 ± 480 |
| Week 24 (2-4 hrs post dose): M1-IVA | 1540 ± 783 |
| Week 24 (2-4 hrs post dose): M6-IVA | 1320 ± 592 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part B + A/B: 1 to < 24 Months |
|---|---|
| Part B + A/B: Absolute Change From Baseline in Sweat Chloride | -62.0 ± 22.2 |
Collected over From Day 1 Through Safety Follow-up Period (up to Day 70 for Part A and up to Week 38 for Part B + A/B). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: 3 to < 24 Months | 0/19 (0%) | 1/19 (5.3%) | 10/19 (52.6%) |
| Part B + A/B: 1 to <24 Months | 0/43 (0%) | 6/43 (14%) | 34/43 (79.1%) |
| Event | Part A: 3 to < 24 Months | Part B + A/B: 1 to <24 Months |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/19 | 0/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/19 | 2/43 |
| ConstipationGastrointestinal disorders | 0/19 | 1/43 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/19 | 1/43 |
| BronchiolitisInfections and infestations | 0/19 | 1/43 |
| Eczema CoxsackiumInfections and infestations | 0/19 | 1/43 |
| Eczema herpeticumInfections and infestations | 0/19 | 1/43 |
| Respiratory tract infection viralInfections and infestations | 0/19 | 1/43 |
| Event | Part A: 3 to < 24 Months | Part B + A/B: 1 to <24 Months |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 4/19 | 24/43 |
| PyrexiaGeneral disorders | 0/19 | 12/43 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/19 | 12/43 |
| VomitingGastrointestinal disorders | 1/19 | 8/43 |
| Alanine aminotransferase increasedInvestigations | 0/19 | 8/43 |
| Upper respiratory tract infectionInfections and infestations | 1/19 | 7/43 |
| Aspartate aminotransferase increasedInvestigations | 0/19 | 7/43 |
| ConstipationGastrointestinal disorders | 1/19 | 6/43 |
| Otitis mediaInfections and infestations | 0/19 | 6/43 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/19 | 6/43 |
All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.
| Age, Customized(Participants) | Ivacaftor (IVA) |
|---|---|
| Part A — 12 to <24 months | 7 |
| Part A — 6 to <12 months | 6 |
| Part A — 4 to <6 months | 4 |
| Part A — 1 to <4 months | 2 |
| Part B+ A/B — 12 to <24 months | 19 |
| Part B+ A/B — 6 to <12 months | 11 |
| Part B+ A/B — 4 to <6 months | 6 |
| Part B+ A/B — 1 to <4 months | 7 |
| Sex: Female, Male(Participants) | Ivacaftor (IVA) |
|---|---|
| Part A — Female | 10 |
| Part A — Male | 9 |
| Part B + A/B — Female | 22 |
| Part B + A/B — Male | 21 |
| Race/Ethnicity, Customized(Participants) | Ivacaftor (IVA) |
|---|---|
| Part A — Hispanic or Latino | 0 |
| Part A — Not Hispanic or Latino | 19 |
| Part A — Not collected per local regulations | 0 |
| Part B + A/B — Hispanic or Latino | 1 |
| Part B + A/B — Not Hispanic or Latino | 42 |
| Part B + A/B — Not collected per local regulations | 0 |
| Race/Ethnicity, Customized(Participants) | Ivacaftor (IVA) |
|---|---|
| Part A — White | 19 |
| Part A — Black or African American | 0 |
| Part A — Asian | 0 |
| Part A — American Indian or Alaska Native | 0 |
| Part A — Native Hawaiian or Other Pacific Islander | 0 |
| Part A — Not collected per local Regulations | 0 |
| Part B + A/B — White | 43 |
| Part B + A/B — Black or African American | 0 |
| Part B + A/B — Asian | 0 |
| Part B + A/B — American Indian or Alaska Native | 0 |
| Part B + A/B — Native Hawaiian or Other Pacific Islander | 0 |
| Part B + A/B — Not collected per local Regulations | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Jun 2022, 72 months.
Results were first posted in Sep 2023, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 72 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →